Leerink Swann Upgrades Corcept Therapeutics (CORT) to Outperform; mproved Confidence in Commercial Outlook
CORT Hot Sheet
Rating Summary:3 Buy, 0 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Leerink Swann upgraded Corcept Therapeutics (NASDAQ: CORT) from Market Perform to Outperform with a price target raised from $3 to $5.
Leerink analyst says, "Discussions with MEDACorp specialists suggest Korlym use could reach 2-3x that of Ipsen's Somatuline or PFE's (MP) Somavert for acromegaly, other pituitary conditions. Adjusting for est. annual revenue by IMS ($22M for Somatuline and $36M for Somavert), a higher est. price point for Korlym (3.5x vs Somatuline, 2.3x vs Somavert), we believe peak US revenue could reach $150-200M. Our 2013E-2015E Korlym US revenue moves from $37/49/69M to $49/105/130M and EPS moves from ($0.05)/($0.27)/ ($0.08) to ($0.03)/$0.05/$0.20. Consensus revenues for 2013E -2015E are $27M/$75M/$145M which may be hard to move up unless Korlym is ultra-premium priced. If we don't see numbers going higher as we transition to the launch setting, our upgrade may prove short-lived."
For an analyst ratings summary and ratings history on Corcept Therapeutics click here. For more ratings news on Corcept Therapeutics click here.
Shares of Corcept Therapeutics closed at $3.12 yesterday, with a 52 week range of $2.51-$5.07.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
Leerink analyst says, "Discussions with MEDACorp specialists suggest Korlym use could reach 2-3x that of Ipsen's Somatuline or PFE's (MP) Somavert for acromegaly, other pituitary conditions. Adjusting for est. annual revenue by IMS ($22M for Somatuline and $36M for Somavert), a higher est. price point for Korlym (3.5x vs Somatuline, 2.3x vs Somavert), we believe peak US revenue could reach $150-200M. Our 2013E-2015E Korlym US revenue moves from $37/49/69M to $49/105/130M and EPS moves from ($0.05)/($0.27)/ ($0.08) to ($0.03)/$0.05/$0.20. Consensus revenues for 2013E -2015E are $27M/$75M/$145M which may be hard to move up unless Korlym is ultra-premium priced. If we don't see numbers going higher as we transition to the launch setting, our upgrade may prove short-lived."
For an analyst ratings summary and ratings history on Corcept Therapeutics click here. For more ratings news on Corcept Therapeutics click here.
Shares of Corcept Therapeutics closed at $3.12 yesterday, with a 52 week range of $2.51-$5.07.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- UPDATE: Williams Financial Group Upgrades Semtech Corp. (SMTC) to Buy; Check Again...Quarter Was Fairly Strong
- Barclays Lowers PT and Estimates on Royal Bank of Canada (RY); Coming Off The Bandwagon
- Needham & Company Reiterates a 'Buy' on UQM Technologies (UQM); Increasing EV Adoption
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
